V3 tip determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A human immunodeficiency virus (HIV-1) envelope glycoproteins

J Virol. 2023 Nov 30;97(11):e0117123. doi: 10.1128/jvi.01171-23. Epub 2023 Oct 27.

Abstract

CD4-mimetic compounds (CD4mcs) are small-molecule inhibitors of human immunodeficiency virus (HIV-1) entry into host cells. CD4mcs target a pocket on the viral envelope glycoprotein (Env) spike that is used for binding to the receptor, CD4, and is highly conserved among HIV-1 strains. Nonetheless, naturally occurring HIV-1 strains exhibit a wide range of sensitivities to CD4mcs. Our study identifies changes distant from the binding pocket that can influence the susceptibility of natural HIV-1 strains to the antiviral effects of multiple CD4mcs. We relate the antiviral potency of the CD4mc against this panel of HIV-1 variants to the ability of the CD4mc to activate entry-related changes in Env conformation prematurely. These findings will guide efforts to improve the potency and breadth of CD4mcs against natural HIV-1 variants.

Keywords: CD4-mimetic compound; Env; V3 loop; entry inhibitor; envelope; gp120; resistance; strain variation; variable region; virus.

MeSH terms

  • Anti-HIV Agents* / chemistry
  • Anti-HIV Agents* / pharmacology
  • Binding Sites / drug effects
  • CD4 Antigens* / chemistry
  • CD4 Antigens* / metabolism
  • HIV Envelope Protein gp120* / chemistry
  • HIV Envelope Protein gp120* / metabolism
  • HIV-1* / chemistry
  • HIV-1* / classification
  • HIV-1* / drug effects
  • HIV-1* / metabolism
  • Humans
  • Molecular Mimicry*
  • Protein Binding / drug effects
  • Receptors, HIV* / metabolism
  • Virus Internalization / drug effects

Substances

  • Anti-HIV Agents
  • CD4 Antigens
  • HIV Envelope Protein gp120
  • Receptors, HIV